Richard W J Groen
Overview
Explore the profile of Richard W J Groen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
2000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruins W, Rentenaar R, Newcomb J, Zheng W, Ruiter R, Baardemans T, et al.
Hemasphere
. 2024 Nov;
8(11):e70039.
PMID: 39544624
Despite significant progress in the treatment of multiple myeloma (MM), relapsed/refractory patients urgently require more effective therapies. We here describe the discovery, mechanism of action, and preclinical anti-MM activity of...
2.
Pastoors D, Havermans M, Mulet-Lazaro R, Brian D, Noort W, Grasel J, et al.
Sci Adv
. 2024 May;
10(20):eadk9076.
PMID: 38748792
Acute myeloid leukemia (AML) driven by the activation of due to chromosome 3q26/ rearrangements is incurable. Because transcription factors such as EVI1 are notoriously hard to target, insight into the...
3.
van der Schans J, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4219-4229.
PMID: 37527004
Purpose: The success of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells illustrates the potential of this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell therapy beyond...
4.
De Matos Simoes R, Shirasaki R, Downey-Kopyscinski S, Matthews G, Barwick B, Gupta V, et al.
Nat Cancer
. 2023 May;
4(5):754-773.
PMID: 37237081
Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic...
5.
Lameris R, Shahine A, Pellicci D, Uldrich A, Gras S, Le Nours J, et al.
Nat Cancer
. 2022 Feb;
1(11):1054-1065.
PMID: 35122066
Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We describe how single-domain antibodies (VHH), specific for the human MHC...
6.
Katsarou A, Sjostrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, et al.
Sci Transl Med
. 2021 Dec;
13(623):eabh1962.
PMID: 34878825
Despite the high remission rates achieved using T cells bearing a chimeric antigen receptor (CAR) against hematogical malignancies, there is still a considerable proportion of patients who eventually experience tumor...
7.
Holthof L, Stikvoort A, van der Horst H, Gelderloos A, Poels R, Li F, et al.
Hemasphere
. 2021 Apr;
5(5):e561.
PMID: 33898931
We have recently shown the strong negative impact of multiple myeloma (MM)-bone marrow mesenchymal stromal cell (BMMSC) interactions to several immunotherapeutic strategies including conventional T cells, chimeric antigen receptor (CAR)...
8.
Holthof L, van der Schans J, Katsarou A, Poels R, Gelderloos A, Drent E, et al.
Clin Cancer Res
. 2021 Apr;
27(13):3793-3803.
PMID: 33883175
Purpose: The microenvironment of multiple myeloma (MM) can critically impair therapy outcome, including immunotherapies. In this context, we have earlier demonstrated that bone marrow mesenchymal stromal cells (BMMSC) protect MM...
9.
Shirasaki R, Matthews G, Gandolfi S, De Matos Simoes R, Buckley D, Raja Vora J, et al.
Cell Rep
. 2021 Jan;
34(1):108532.
PMID: 33406420
Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3 ligases to induce degradation of target oncoproteins and exhibit potent preclinical antitumor activity. To dissect the mechanisms regulating tumor cell sensitivity...
10.
Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, Mandhane S, et al.
Hemasphere
. 2020 Sep;
4(5):e463.
PMID: 32923984
No abstract available.